


FIGURE 1

Tumor Volume			
Saline Infusion	Saline PRVI	SD-101 Infusion	SD-101 PRVI
135.892224	55.67284	39.16125	328.33751
1143.23323	128.505488	584.583168	19.20996
98.97316	158.682636	86.8900175	0.01875
197.308272	281.57625	1778.87162	
17.075591	281.57625	254.0664	
151.381696		855.8664	
169.885156		135.210384	
647.224512		362.905613	
255.102801		430.563328	
366.235506		249.716448	
1146.12505		116.067848	
209.776248		32.8763655	
Mean 378.184454	181.202693	410.564903	115.855407
SEM 113.005648	44.2671404	143.066465	106.385398

FIGURE 2A




FIGURE 2B

	Tumor Weight			
	Saline Infusion	Saline PRVI	SD-101 Infusion	SD-101 PRVI
	0.52	0.32	0.41	0.44
	0.87	0.37	0.62	0.29
	0.39	0.26	0.34	0.08
	0.79	1.24	1.24	
	0.17	0.66	0.66	
	0.38	0.65	0.65	
	0.34	0.63	0.28	
	0.59	0.63	0.42	
	0.46		0.35	
	0.71		0.5	
	0.62		0.53	
	0.28		0.2	
Mean	0.51	0.595	0.51666667	0.27
SEM	0.0614102	0.10890691	0.07827045	0.10440307

FIGURE 3A




FIGURE 3B



Normalized Labeled SD-101 Signal Intensity in Pancreas
(all data)
**p=0.000
Signal in Non-Target Tissue
Signal in Target Tissue
Normalized Signal Intensity
22
20
18
16
14
12
10
8
6
4
2
0

FIGURE 4



Normalized Signal Intensity
20
18
16
14
12
10
8
6
4
2
0
**p=0.000
Signal in Non-Target Tissue
Signal in Target Tissue
Normalized Labeled SD-101 Signal Intensity in Pancreas
(outlier removed)

FIGURE 5



Treated Tissue Volume
p=0.010
PRVI SEAL
PRVI endhole
Tissue Volume (cm³)
10
9
8
7
6
5
4
3
2
1
0

FIGURE 6



Signal Intensity of Labeled SD-101
Signal Intensity (Iu)
5000
4500
4000
3500
3000
2500
2000
1500
1000
500
0
p=0.025
PRVI Endhole
PRVI SEAL

FIGURE 7



Treated Tissue Volume
p=0.007
PRVI SEAL
PRVI Endhole
Tissue Volume (cm³)
10
9
8
7
6
5
4
3
2
1
0

FIGURE 8



Signal Intensity of Labeled SD-101
Signal Intensity (Iu)
5000
4500
4000
3500
3000
2500
2000
1500
1000
500
0
p=0.019
PRVI SEAL
PRVI Endhole

FIGURE 9




FIGURE 10B




FIGURE 10A



PHASE 1
SINGLE AGENT SD-101 PRV/PEDD
DOSE ESCALATION
SD-101 4 mg
(n=3-6)
SD-101 7 mg
(n=3-6)
SD-101 0.5 mg
(n=3-6)
SD-101 SINGLE AGENT
RP2D EXPANSION
(n=10 optional)
PHASE 1b
SD-101 PRV/PEDD DOSE ESCALATION +
SYSTEMIC CHECKPOINT INHIBITION
SD-101 RP2D + Pembro
(n=3-6)
SD-101 RP2D-1 + Pembro
(n=3-6)
OPTIONAL COHORT
WITH SD-101 RP2D +
NIVO/IPI
OPTIONAL EXPANSION
COHORT WITH RP2
REGIMEN (N=10)

FIGURE 11